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Abstract
Background: Construction of conditionally-replicative Adenovirus (CRAd) is complex and time-
consuming. While homologous recombination (HR) using a two-plasmid system in bacteria is
commonly used to generate CRAds, alternative methods may be required when HR fails.
Previously,  in vitro ligation has been suggested to facilitate construction of E1/E3-deleted,
replication-incompetent  Ad vectors. However, in vitro l i g a t i o n  h a s  o n l y  r a r e l y  b e e n  u s e d  t o
generate CRAds and may be a complex procedure for molecular biologists who are not experts in
the field.
Methods and Results: A modified in vitro ligation approach was developed to construct a double-
targeted, E1B55k-deleted CRAd. The method allowed the incorporation of a tumor-specific
promoter, e.g. the heat-shock protein 70 (hsp70) promoter, upstream of E1a, deletion of the
E1B55k gene, and HR-free cloning of the recombined E1 55k gene into the Ad genome. The genetic
structure of the CRAd was confirmed using restriction analysis and PCR. The replication rate of
the hsp70E1Δ55k CRAd was 1.5–2% of Ad without E1Δ55k deletion.
Conclusion: A 3-step cloning approach can generate a double-targeted, E1B55k-deleted CRAd
using a straight-forward, modified in vitro ligation procedure.
Introduction
Adenoviruses (Ad) are excellent gene transfer vectors and
are extensively used for high-level transgene expression in
vitro and in vivo. One of the attributes rendering Ad vectors
particularly well suited for this purpose is the capacity to
manipulate their genome. Typically, Ad vectors are con-
verted into mammalian gene transfer vectors by replacing
the E1 gene with the foreign gee of interest. E1 deletion
serves two goals, i.e. to increase the cloning capacity to 5
kb (and to 8 kb if the E3 region is also deleted) and to
render Ad vectors replication-incompetent.
Two approaches to have been traditionally used to con-
struct recombinant Ad vectors. First, homologous recom-
bination (HR) in either packaging cell lines, bacteria or
yeast. Second, in vitro ligation using standard molecular
biology procedures. These two methods rely on the fact
that purified, linear Ad DNA is infectious, resulting in
recombinant Ad virions after transfection into packaging
cell lines. In vitro ligation was the first approach to manip-
ulate the Ad genome. However, it was abandoned for
many years because the large, 35.9 kb Ad genome that
encodes more than 50 gene products, generally lacks suf-
ficient unique restriction sites. To overcome this limita-
tion HR was developed, initially using ClaI digested viral
DNA. Next, the viral DNA was transfected into the pack-
aging cell line to undergo spontaneous, albeit inefficient
HR. To enhance HR efficiency in mammalian cells, a two-
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plasmid rescue system was developed [1,2]. According to
this method, two non-infectious plasmids with two over-
lapping Ad sequences were co-transfected into 293 cells,
yielding an infectious recombinant Ad. The first use of the
two plasmid system to construct recombinant Ad vectors
incorporating foreign transgenes was developed by Gra-
ham's lab [3]. The manipulated plasmid encoding the
transgene has been termed the shuttle plasmid and was
co-transfected into 293 cells with along with a large plas-
mid containing the Ad backbone, incorporating a 2.2 kb
ampicillin resistance gene in the XbaI site. Because neither
plasmid is infectious alone, recombinant E1-deleted Ad
vectors were generated as a result of HR between the over-
lapping regions. Further modifications were made by Bett
who removed a large fragment from the E3 region and
introduced a unique PacI site immediately adjacent to the
Ad inverted terminal repeat (ITR), allowing linearization
of the backbone plasmid [4]. HR thus employs two plas-
mids with overlapping sequences to be recombined in E1-
compelmenting 293 or 911 cells.
To construct Ad vectors encoding heterologous genes, the
smaller plasmid, termed the shuttle plasmid and contain-
ing the left ITR, a packaging signal and a sequence over-
lapping with the larger Ad backbone plasmid, was
engineered to encode the gene of interest. The larger plas-
mid, contained almost all the entire Ad genome devoid of
the packaging signal and the E1 and E3 genes, was co-
transfected into 293 cells where HR was to generate the
recombinant Ad genome. However, this procedure
required plaque purification of the recombinant Ad vector
by screening individual clones. In addition, HR in 293
cells occurs in low frequency, is a time-consuming proce-
dure and recombinant Ad vector progeny may be contam-
inated with the wild-type Ad virus. Thus, to obtain a pure
Ad preparation at least two rounds of plaque purification
assays may be required. To facilitate vector selection in
cells, screening for the recombinant virus has been facili-
tated by using counter-selection methods, extensive frag-
mentation of Ad DNA complexed with the terminal
protein or by using Cre-lox-mediated recombination [5].
These methods had the advantage that copies of the
recombinant viral DNA were purified from clones and
could therefore generate homogenous Ad preparations.
Optimization of two-plasmid HR was further reported in
bacterial systems [6], using reconstitution of the sequence
of the recombinant Ad in BJ5183 E. coli strains before
transfection into 293 cells. Another advantage was prepa-
ration of the recombinant Ad genome in large quantities
before transfection into 293 cells. The BJ5183 bacterial
strain is recombination-proficient because i) it lacks the
RecBCD enzyme and ii) it contains the RecF enzyme
allowing DNA strand exchange between two linear DNA
molecules that share at least 50 homologous bp at each
end. One of these DNA molecules is the linearized shuttle
plasmid previously subcloned with the heterologous gene
and containing a bacterial origin of replication, a kanamy-
cin-resistance gene and the left and right inverted terminal
repeats (ITR) segments of the Ad genome.
While HR in bacteria has been generally accepted, it
requires multiple steps in different E. coli stains. In addi-
tion, while in mammalian cells, the rate-limiting recom-
bination step produced only the correct viral product of
recombination, constructing the Ad genome by recombi-
nation in E. coli or yeast does not guarantee a correct,
infectious recombinant Ad DNA. Unpredicted recombi-
nation events can occur, especially in yeast [7], requiring
a thorough analysis of the recombinants to exclude clones
that are unable to generate virus.
On this basis, in vitro ligation would be an attractive alter-
native procedure to HR. Until a decade ago, in vitro liga-
tion was rarely used because of lack of unique restriction
sites, low efficiency, the need for plaque purification to
exclude wild-type Ad, and the risk of transgene-null Ad
vectors due to self-religation. A major breakthrough in the
methodology of in vitro ligation was the independent
introduction of novel unique cleavage sites into the Ad
genome by three independent groups [7-10]. Thus, in vitro
ligation uses whole isolated Ad DNA cleaved with unique
restriction sites flanking the E1-deleted region. The
digested viral DNA is then ligated directly to a DNA frag-
ment containing the left end joined to the gene of interest,
followed by transfection of the recombinant Ad DNA into
the packaging cell line [11]. One of the in vitro ligation
techniques was developed by Mizuguchi and Kay via the
introduction of unique intron-encoded endonuclease
sites within the Ad genome [8,9] ('AdenoX™'). The I-CeuI/
PI-SceI  intron-encoded endocnucleases uniquely cleave
unusually long homing sequences ranging from 15 to 39
bp, rendering these restriction sites rare and ideal for use
as cloning sites in large genomes such as Ad. The E1-
deleted region is flanked by the two unique cleavage sites
of I-CeuI and PI-SceI, and in between a SwaI cleavage site
is used to inhibit re-ligation of the transgene-null Ad back-
bone. To produce E1-deleted, replication-deficient Ad vec-
tors, this technique requires two cloning steps. First,
subcloning the transgene into a I-CeuI/PI-SceI  flanked,
multicloning site (MCS) within the shuttle plasmid
upstream of a CMV promoter and downstream of a poly
A signal (Fig. 1d). Thus, cutting the recombinant shuttle
plasmid with I-CeuI and PI-SceI provides a full expression
cassette based on the foreign ORF cDNA inserted into the
MCS. Second, cloning the recombinant I-CeuI/PI-SceI
fragment from the shuttle vector into the I-CeuI/PI-SceI
restriction site within the Ad backbone genome. Produc-
tion of the recombinant Ad genome is thus truly in vitro
and independent of bacterial or mammalian systemsVirology Journal 2009, 6:18 http://www.virologyj.com/content/6/1/18
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Overall Schematic diagram of the 3-step cloning strategy to generate CRAd-hsp70E1Δ55k using a modified in vitro ligation sys- tem Figure 1
Overall Schematic diagram of the 3-step cloning strategy to generate CRAd-hsp70E1Δ55k using a modified in 
vitro ligation system. To generate a double-targeted CRAd, a TSP-regulated E1ΔE1B55k fragment was reintroduced into an 
E1/E3 deleted Ad backbone. a, the 383-bp human hsp70 promoter was cut with SalI, Klenow-dNTP blunted, XhoI digested, gel 
purified and inserted into the EcoRV/XhoI site in pMKE1 (b), to replace the MK promoter and generate phsp70E1 (c). Next, to 
remove the E1B55k fragment, phsp70E1 was digested with XhoI, Klenow dNTP blunted and digested with KpnI (c). Simultane-
ously, to remove the CMV promoter yet maintain the polyA signal, pShuttle from the Adeno-X system was digested with MfeI, 
Klenow dNTP blunted and digested with KpnI (d). Thus, the pShuttle of the AdenoX system was modified to encode a CMV-
promoter deleted, TSP-regulated, E1B55k-deleted E1 gene in phsp70E1Δ55k (e). Next, to generate the recombinant CRAd 
genome, pAdhsp70E1Δ55k, the hsp70E1Δ55k fragment was removed from phsp70E1 with I-CeuI and PI-Sce-I digestion, purified 
via agarose gel electrophoresis and ligated into the pre-I-CeuI/PI-Sce-I-digested Ad backbone plasmid (f). SwaI digestion elimi-
nated the chance of religation of the Ad backbone plasmid without recombination. MK promoter, the human 2.6 kb gene pro-
moter. CMV promoter, the human cytomegalovirus immediate-early gene promoter. BGH polyA, the bovine growth hormone 
early mRNA poly-adenylation signal. Grey-filled arrows indicate fragments excised for further cloning.
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encoding the enzymes essential for HR. However, because
the shuttle plasmid contains a CMV promoter upstream of
the MCS, tight control of transgene expression may be
lost.
Similarly, Souza and Armentano employed the same logic
for the construction of Ad serotype 2 vectors using I-CeuI
and SnaBI sites [10]. However, their pAdvantage™ system
has a substantially lower reported cloning efficiency than
the method reported by Mizuguchi and Kay [8,9].
Danthinne also developed a HR-free system ('Adeno-
Quick™') for preparation of replication-deficient Ad, using
a relatively complex system requiring encapsidation of the
recombinant Ad genome into λ phage particles [7].
In the context of oncolytic Ad, re-introduction of modi-
fied E1 cassettes is required to construct conditionally-rep-
licative Ad (CRAd). The superiority of CRAds over
replication-deficient Ad vectors for cancer includes selec-
tive amplification of the cancer cell-killing capacity while
relatively sparing normal cells. The attributes of CRAds
include lysis of tumor cells that are resistant to standard
therapy, selective cancer cell killing and induction of cell-
mediated anti-tumor immunity. Because there is currently
no established effective therapy for disseminated Ad infec-
tion, CRAd replication should be stringently restricted to
permissive cancer cells. To this end, two genetic
approaches have been reported involving either insertion
of a tumor-specific promoter (TSP) upstream of E1a and
E4 or partial deletion of E1 genes, e.g. E1B55k or the E1A
conserved region 2 (CR2) [12]. Infrequently, double-tar-
geted CRAds may combine both types of genetic modifi-
cations.
In contrast to generation of replication-deficient Ad vec-
tors, construction of CRAds is not straight-forward and
may be time and labor-consuming. Two molecular strate-
gies to construct CRAds have been described. First, and by
far more popular, HR has been used by many groups to
recombine an E1-encoding shuttle plasmid with the
pAdEasy backbone plasmid [13-22]. The second strategy
to generate CRAds involves in vitro ligation [23-28]. The
setbacks of HR in the context of CRAds include the unpre-
dicted chance of in vivo HR in BJ5183 bacteria and the lack
of sufficient plasmid DNA production in BJ5183 bacteria
required to allow diagnostic restriction analysis, thereby
requiring transfer to candidate plasmids into other E. coli
strains, such as DH5α[29].
Despite the utility of HR, potentially targeting virtually the
entire Ad genome, when HR fails, alternative approaches
to construct CRAds may be required. The two reported
approaches to generate CRAds using in vitro ligation differ
in their methodologies [23-27]. First, Hernandez-
Alcoceba et al have reintroduced E1a and E4 into the Ad
genome [23,24]. To generate a CRAd, direct cloning of
TSPs upstream of E1a or E4 within the Ad backbone is fea-
sible using unique restriction sites flanking the promoter
regions of E1A (BstBI sites) and E4 (I-CeuI and SwaI sites)
[23,24].
The setbacks of this approach may include the complete
lack of the two E1B genes and the large Ad backbone con-
taining the E1 and E4 genes, rendering manipulation of
E1/E4 within the large Ad genome less efficient than in
smaller shuttle plasmids which are readily amenable for
genetic modifications.
The second in vitro ligation approach to generate CRAds
without HR was developed by Danthinne [25-28]. This
method is based on the AdenoQuick™ system, originally
developed to construct replication-deficient E1-deleted
Ad vectors [7]. To construct CRAds, this strategy involves
re-introduction of modified E1 genes into a shuttle plas-
mid containing the Ad left arm and the Ad packaging sig-
nal. While several CRAds were reported using this system
[25-28], the process is rather complex and may require
multi-order fragment ligation [25,27] and a cos site next to
the gene of interest for subsequent in vitro packaging into
phage λ after cloning the recombinant Ad backbone [7].
Thus, this in vitro methodology for CRAd construction
may be too labor and time-consuming to investigators
who are not experts in the field.
In the current study we report a simplified, HR-free in vitro
ligation approach to construct a double-targeted, TSP-reg-
ulated, ΔE1B55k CRAd involving a direct, 3-step cloning
strategy. This modified in vitro ligation system is a simple
and efficient method to construct recombinant ΔE1B55k
CRAds.
Results and discussion
As a proof of principle to construct a double-targeted
CRAd via in vitro ligation, CRAd-hsp70E1Δ55k was gener-
ated using two genetic modifications, e.g. cloning the
heat-shock 70 promoter (hsp70) TSP upstream of the E1A
gene and deletion of the E1B55kD gene (Fig. 1). Overall,
we combined components from the AdEasy [6] and the
Adeno-X [8,9] systems. An E1-encoding plasmid, con-
structed on the basis of the pShuttle of the AdEasy system
[14], was employed to subclone the hsp70 promoter
upstream of E1 (Fig. 1b). However, instead of using this
shuttle plasmid for HR, we further subcloned an E1B55k-
deleted, TSP-regulated E1 construct from this shuttle plas-
mid into the shuttle vector of the Adeno-X system (Fig.
1d). The modified E1 construct was then directly cloned
into an E1/E3 deleted Ad backbone genome using in vitro
ligation instead of HR (Fig. 1e, f).Virology Journal 2009, 6:18 http://www.virologyj.com/content/6/1/18
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The first step involved insertion of a TSP upstream of E1.
The human hsp70 promoter was selected as a TSP because
hsp70 expression has been associated with malignancy
[30]. Furthermore, heat, ultrasound and magnetic reso-
nance imaging (MRI)-inducible transcription may enable
spatial and temporal control of hsp70-regulated gene
expression [20,31,32]. Thus, regulation of E1A  by the
hsp70 promoter may be a rational TSP approach in the
context of CRAds. To insert the 383 bp hsp70B promoter
(-270→+113) upstream of the E1A  gene, the SPV-110
plasmid was digested by SalI, Klenow-dNTP blunted and
cut with XhoI (Fig. 1a). Klenow treatment was required to
blunt the overhang SalI end because the hsp70 promoter
was inserted into an EcoRV/XhoI site within the pMKE1
(Figs. 1b and 2). pMKE1 was originally derived from the
shuttle plasmid of the AdEasy system via sequential clon-
ing of E1 components into the multiple cloning site [14].
pMKE1 contains the complete E1 and protein IX genes
and is deleted of the native E1a promoter (Δ324–488 nt
from the left Ad arm). However, in contrast to the next
step of HR in the AdEasy system, the XhoI/KpnI digested
fragment, encompassing the hsp70 promoter, E1a  and
E1B19k, and deleted of the E1B55k gene by KpnI diges-
tion, was directly subcloned into the pShuttle of the
Adeno-X system (Fig. 1d). Within the latter pShuttle, the
CMV promoter is retained to drive expression of the het-
erologous transgenes in replication-deficient Ad vectors
[8,9]. However, because CRAds require a TSP upstream of
E1A, the CMV promoter was excised via MfeI/KpnI diges-
tion and replaced by the hsp70E1Δ55k construct, imme-
diately flanked by the stop codons of the AdenoX pShuttle
(Figs. 1c–e and 2).
Next, the I-Ceu-I/PI-Sce-I  fragment was excised from
phsp70E1Δ55k shuttle plasmid, and cloned into the I-
Ceu-I/PI-Sce-I flanked, E1-deletion site within the Adeno-
X backbone plasmid to produce pAdhsp70E1Δ55k (Figs.
1e-f, 3). Of note, because the E1-deleted Ad backbone
pAdeno-X is also deleted of the E1a promoter (deleted
from nt. 342 of the left arm of the Ad genome), this clon-
ing approach results in a recombinant CRAd genome with
TSP-regulated  E1a  expression. This ligation procedure
resulted in the correct recombinant CRAd genome in 10%
of ampicillin-resistant colonies screened by restriction
analysis and confirmed by PCR (Fig. 3). After large scale
preparation of the recombinant plasmid with Qiagen
Maxi-kit, the recombinant pAdhsp70E1Δ55k plasmid was
linearized with PacI digestion and transfected into 293
cells to produce CRAd-hsp70E1Δ55k without the need for
plaque purification. Absence of wild-type Ad contamina-
tion in CRAd-hsp70E1Δ55k stocks was confirmed after
three viral passages by absence of E1B55k DNA detection
via real-time PCR (Fig. 4a). Thus, a double-targeted CRAd
was generated using straight-forward HR-free, in vitro liga-
tion.
Of note, CRAd-hsp70E1Δ55k manifested a decreased
cytopathic effect relative to AdCMVE1 (not shown), deriv-
ing from attenuated viral replication. The relative viral
DNA replication rate of CRAd-hsp70E1Δ55k after 36
hours was 1.98% and 1.52% of Ad viruses driven by the
CMV promoter (AdCMVE1) or the native E1a promoter
(Ad5luc3), respectively (Fig. 4b). The fidelity of the hsp70
promoter in CRAd hsp70E1Δ55k was not maintained
during heat induction, i.e. there was no heat-shock induc-
tion of CRAd hsp70E1Δ55k DNA replication (not
shown). This finding is in accordance with previous
reports of hsp70 promoter in replicating Ad [20,33]. Thus,
while heat-shock enhances the oncolytic effect of CRAds
in general [34], the hsp70 promoter does not provide
tight control in the context of CRAd-hsp70E1Δ55k.
CRAd-hsp70E1Δ55k differs from two previously-reported
CRAds with hsp70 promoters. The first hsp70 CRAd con-
tained a ΔE1B55k deletion, but the hsp70 promoter did
not drive E1a expression but rather a cytosine deaminase/
thymidine kinase (CD/TK) suicide gene [33]. The second
hsp70 CRAd combined both hsp70 and mouse tyrosinase
promoters to drive expression of E4, without tumor-tar-
geted partial E1a or E1B  deletions [20]. Of note, both
these hsp70-CRAds, as the vast majority of other CRAds,
were produced using HR.
Deletion of the E1B55k gene was the genetic modification
in the first CRAd, dl1520 (Onyx-015) [35]. The deletion of
a viral gene such as E1B55k that inactivates cellular regu-
latory proteins, e.g. p53, was suggested to restrict CRAd
replication to cancer cells with specific genetic mutations
thought to complement the viral genetic loss of function
[35]. The Ad E1B  gene encodes two major species of
mRNAs. One mRNA codes for a 19-kDa polypeptide
(E1B19k) and the other codes for a 55-kDa protein
(E1B55k). The two proteins are encoded by alternative
reading frames and share no sequence homology. During
Ad infection the E1B proteins inhibit apoptosis to allow
Ad protein production and viral DNA replication. While
the E1B19k protein has an anti-apoptotic effect mimick-
ing the cellular bcl-2, The E1B55k protein exerts its anti-
apoptotic effect via inhibition of p53-induced transcrip-
tion. In addition, E1B55K induces a cellular environment
conductive for viral protein synthesis via a complex with
the Ad E4 ORF6 protein. This complex inhibits the trans-
port of host cellular mRNA from the nucleus to the cyto-
plasm while selectively stabilizing and transporting viral
mRNA. Because approximately half of human cancer
types are mutated for p53, deletion of the E1B55k gene has
been suggested as a tumor-targeted approach suggesting
conditional Ad replication only in p53-mutant cells [35].
This approach has been subsequently disputed [36], but
E1B55k  deletion is still considered one of the genetic
approaches to mitigate Ad replication in normal cellsVirology Journal 2009, 6:18 http://www.virologyj.com/content/6/1/18
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[12], probably via loss of E1B55k-mediated late viral RNA
export rather than p53-inactivation [36]. The cloning
strategy reported here allows the deletion of E1B55k via
digestion of the E1-encoding vectors pMKE1 or phsp70E1
at the kpnI site. A prior step of subcloning a TSP upstream
of the E1a gene allows the construction of a double-tar-
geted E1 gene for subsequent cloning into the Ad genome.
Thus, in view of the relatively complex construction of
CRAds using HR [13-22] and previously-reported in vitro
ligation approaches [23-28], the method we propose has
the advantage of only 3 standard cloning steps required to
produce a double-targeted CRAd.
The drawbacks of this approach include limitation to E1-
encoding expression cassettes free of ClaI, SwaI and PacI,
BstBI and Psp1406I sites. In addition, in vitro ligation is
generally limited to recombining the ends of the Ad
genome at the E1 and E4 regions, while HR can use line-
arized vectors to target virtually any region in the Ad back-
bone to allow point mutations and small deletions.
In conclusion, HR and in vitro ligation have been fre-
quently and rarely employed to generate CRAds, respec-
tively. The simplified in vitro ligation system described
herein may be efficiently employed to construct TSP-
driven, E1 55k-deleted CRAds.
Materials and methods
Cells, plasmids and reagents
293 and A549 cells were from ATCC (Manassas, VA) and
maintained in DMEM supplemented with 10% fetal calf
serum, 100 units/ml of penicillin and 100 μg/ml of strep-
Validation of hsp70E1Δ55k fragment Figure 2
Validation of hsp70E1Δ55k fragment. a. Schema of the recombinant hsp70E1Δ55k cassette obtained by XhoI/KpnI diges-
tion of phsp70E1. b. The construct of phsp70E1 (see Fig. 1c) was confirmed by PCR using complementary oligonucleotide 
amplimers of sequences flanking the indicated fragments of the template plasmid. c. Candidate clones for phsp70E1Δ55k (see 
Fig. 1e) were screened using digestion analysis with KpnI and XbaI. Diagnostic fragments obtained are marked with an arrow. 
M-The 1 kb DNA ladder from Gibco was used as DNA size marker.Virology Journal 2009, 6:18 http://www.virologyj.com/content/6/1/18
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tomycin in 5%CO2. The SPV-110 plasmid (StressGen,
Victoria, Canada) contains the 383 bp human hsp70B
promoter (GenBank accession no. X13229), flanked by
XhoI  and  SalI  restriction sites. pMKE1 was previously
described [14]. Briefly, it was derived from the shuttle
plasmid of the pAdeasy system where the multi-cloning
site and right arm in the pAdeasy pShuttle were replaced
by the 2.6 kb midkine (MK) promoter and the complete
Ad E1 region and protein IX genes, devoid of the native Ad
E1a promoter region (Δ324–488) [14]. pShuttle and pAd-
enoX backbone were from Clontech, San Jose, CA (cur-
rently BD, Franklin Lakes, NJ). All restriction enzymes and
ligase were from New England BioLabs except for I-CeuI
and  PI-Sce-I  (Clontech). All DNA purificaiotn and cell
lysis kits were from Qiagen (Valencia, CA).
Standard molecular biology procedures for in vitro CRAd 
construction
Screening for recombinants was with miniprep plasmid
DNA prepared by standard alkaline lysis kit (Qiagen),
restriction analysis and 0.8% agarose gel electrophoresis
with ethidium bromide staining. Large scale Ad backbone
plasmid and recombinant Ad plasmids were purified by
phenol-chloroform extraction and ethanol precipitation
or Maxi-prep kit (Qiagen). Digested hsp70 promoter and
hsp70E1Δ55k fragments were purified by gel extraction
after agarose gel electrophorsesis. To clone the
hsp70E1Δ55k fragment from phsp70E1 into pShuttle
(Fig. 1c, d), a ratio of 3:1 (insert: digested pShuttle) was
optimal. Ligation of the I-Ceu/I-PI-Sce-I  flanked
hsp70E1Δ55k fragment (after digesting 1 μg of
phsp70E1Δ55k for 3-hrs) into 750 ng of the pAdeno-X
backbone was performed with T4 DNA ligase overnight at
16°C. Cloning efficiency was enhanced by heat inactiva-
tion of the T4 DNA ligase and by digesting with SwaI that
recognizes a unique site between the I-Ceu-I/PI-Sce-I sites
of the Adeno-X backbone (but not within the I-Ceu-I/PI-
Sce-I fragment from phsp70E1Δ55k), thereby preventing
religation of the E1-deleted backbone. The recombinant
pAdhsp70E1Δ55k plasmid was used to transform 50 μl
chemical-competent DH5α bacteria via 60 sec heat-shock
and selection with ampicillin (100 μg/ml).
To rescue CRAd-hsp70E1Δ55k, 5 μg of pAdhsp70E1Δ55k
were linearized with PacI to expose both ITRs and DNA
was purified by phenol-chloroform. Next, to transfect 293
cells, 4 μg of the digested DNA was mixed at room temper-
ature with 20 μl Lipofectamine (Life Technologies),
diluted in 500 μl of OptiMEM (Life) and added to the
DMEM media for 4-hrs. Media was replaced to growth
media and 293 cultured for 12 days until a cytopathic
effect was observed. After three cycles of viral propagation,
CRAd-hsp70E1Δ55k was purified using double CsCl den-
sity gradient centrifugation and tittered using both DNA
optical density at 260 nm (viral particle [vp] concentra-
tion) and plaque assays in HEK 293 cells (infectious units
[iu]). The vp/iu ratio was 100.
Validation of constructs using PCR
The oligonucleotide primer corresponding to the human
hsp70B promoter was sense strand 5'-AGCTAGAACCTTC-
CCCGCG-3'. The oligonucleotide primers corresponding
to the Ad E1a  were sense strand 5'-TCTTGAGT-
GCCAGCGAGTAG-3' and the antisense strand was 5'-
AAGTCCAAAGGTTGCCCAGG-3'. The oligonucleotide
primers corresponding to the Ad E1B were sense strand 5'-
TTTTCTGCTGTGCGTAACTT-3' and the antisense strand
was 5'-ATCTTCATCGCTAGAGCCAA-3. For whole E1 PCR
the forward primer was the sense sequence of E1a and the
reverse prime was the antisense sequence of E1B. The oli-
gonucleotide primer corresponding to the forward I-Ceu-I
Validation of pAdhsp70E1Δ55k Figure 3
Validation of pAdhsp70E1Δ55k. a. Schema of the recom-
binant Ad plasmid pAdhsp70E1Δ55k. b. Restriction analysis 
to confirm the structure of pAdhsp70E1Δ55k by XbaI/KpnI 
E1 cleavage. The diagnostic fragment is marked with an 
arrow. Control was the Adeno-X Ad backbone plasmid. c. 
Standard PCR was used to confirm the correct structure of 
the recombinant CRAd-Adhsp70E1Δ55k. The purified 
recombinant virus was directly applied in the various indi-
cated PCR reactions encompassing the modified E1 gene 
within the PI-SceI/I-CeuI site of the recombinant CRAd.
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sense strand was 5'-TAACTATAACGGTCCTAAGGTA-'3
and the reverse PI-Sce-I primer was 5'-TTTCTCCGCAC-
CCGACATAGA-'3. To analyze viral DNA with standard
PCR, 1 μl of purified CRAd-hsp70E1Δ55k was directly
applied into a 50 μl PCR reaction with 1 μl of each primer,
at 30 cycles of 95°C 1-min denaturation, 50°C 2-min
annealing and 72°C 2.5-min extension.
Analysis of CRAd replication with real-time PCR
One hundred and fifty thousand A549 cells were infected
in triplicates with 10 MOI of CRAd hsp70E1Δ55k,
AdCMVE1 or Ad5luc3. Thirty-six hours later (to allow one
cycle of complete Ad DNA replication) cellular DNA was
extracted using a Blood DNA purification kit (Qiagen).
Real-time PCR conditions were 35 cycles of (94°C, 20 s→
55°C, 20 s → 72°C, 30 s). Ad backbone plasmid
pTG3602 (Transgene, Strasbourg, France) was available
for plotting a standard curve for the E4 copy number. E4
copy numbers were normalized to the  -actin DNA copy
number.
One μl of eluted DNA sample was analyzed by real-time
PCR amplification to measure Ad E4 copy number as an
indicator of CRAd replication and E1B copy number to
confirm  E1B55k  deletion in CRAd-hsp70E1Δ55k and
absence of wild type Ad contamination. The oligonucle-
otide primers corresponding to the E1B sense strand were
5'-GACAGGGCCTCTCAGATGCT-3' (Ad genome 3075–
3094) and the antisense strand was 5'-5'-TGGCTACGT-
GAATGGTCTTCAG-3' (Ad genome 3144–3123). The oli-
gonucleotide primers corresponding to the E4 sense
strand were 5'-TGACACGCATACTCGGAGCTA-3' (Ad
genome 34885–34905) and the antisense strand was 5'-
TTTGAGCAGCACCTTGCATT-3 (Ad genome 34977–
34958). The TaqMAn probe was 5'-CGCCGCCCAT-
GCAACAAGCTT-3' (Ad genome 34930–34951).
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